Could placental stem cell vesicles ease COVID-19?
NCT ID NCT07664696
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single IV dose of placental stem cell vesicles (XoGlo Pro) against placebo in 64 adults with mild to moderate COVID-19. The main goal is safety, with a secondary focus on how quickly symptoms resolve. Researchers aim to see if these tiny cell particles can calm the immune response and speed recovery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- placental stem cell vesicles (XoGlo Pro)
- What this could lead to
- If it works, this could offer a new way to reduce COVID-19 symptoms and speed up recovery without needing long-term medication.
- What could go wrong
- This is an early phase trial with only 64 people, so results may not apply broadly. The treatment could cause side effects or prove no better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult subjects of either gender aged more than 18 years. 2. Body Mass index (BMI) between ≥25 and ≤39.9 kg/m2. 3. Duration (in days) of COVID-19 symptoms prior to randomization is a \> 2 days and ≤ 10 days of COVID-19 symptoms. 4. Two (2) positive (rapid) antigen diagnostic tests for SARS-CoV-2 (tests listed under FDA EUA) and administered within 2 hours of each other. Enrolled subjects will undergo subsequent molecular standard reverse transcriptase polymerase chain reaction (rt-PCR) assay. Enrolled subjects with a negative PCR test will be replaced by other individuals.) 5. Subjects with a minimal baseline severity score for COVID-19-related symptoms defined as at least two symptoms with a score of 2 or higer, using normalized grading scale. 6. Female subjects of non-childbearing potential (e.g., non fertile, pre-menarche, permanently sterile \[e.g., underwent hysterectomy, bilateral salpingectomy or bilateral ovariectomy\] or post-menopausal \[history of no menses for at least 12 months without an alternative medical cause\] or Woman of childbearing potential\* with a negative serum or urine pregnancy test Exclusion Criteria: 1. Subjects who test positive for SARS-CoV-2 using a virologic test but have no symptoms consistent with COVID-19. (Asymptomatic or presymptomatic infection). 2. Subjects who have SpO2 \<94% on room air at sea level (Severe illness). 3. Subjects who have respiratory failure (Critical illness). 4. Subjects who have septic shock (Critical illness). 5. Subjects who have multiple organ dysfunction (Critical illness). 6. Subjects presenting with an underlying medical condition or risk factor that conclusively disposes that subject to a higher risk for progression to severe COVID-19, as per the CDC's Systematic Review Process. 7. Subjects hospitalized within the previous 15 days. 8. Subjects discharged from the Emergency Room within the previous 15 days. 9. Subjects not expected to survive for three (3) months due to other pre-existing medical conditions such as end-stage neoplasm or other diseases. 10. Less than 18 years.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?
- Can an oral drug stop COVID-19 from turning deadly?
- Can COVID-19 rapid tests slip into HIV and TB clinics without disrupting care?